Experimental drug shows promise against deadly MRSA infectio
The race to find new treatments against deadly MRSA has a new contestant in the form of an experimental drug that successfully treated the infections of the drug-resistant bacteria in animals. The compound, called TXA709, also restored the effectiveness of cefdinir - an antibiotic in use for nearly 20 years that had lost its ability to deal with MRSA.
This was the result of a new study led by Rutgers University in Piscataway, NJ, and published in the journal Antimicrobial Agents and Chemotherapy. Senior author Daniel Pilch, associate professor in pharmacology at Rutgers Robert Wood Johnson Medical School, explains the significance of the finding:
"This is important because even though TXA709 is effective on its own in treating MRSA, combining it with cefdinir - used to treat a wide range of bacterial infections like strep throat, pneumonia, bronchitis and middle ear and sinus infections - makes it even more efficacious, while also significantly reducing the potential for the MRSA bacteria to become resistant in the future."

Read more:
A●●●●●h S●●●●●r and 3 others like this